Gland Pharma Q1 FY27: consolidated PAT up 47% YoY to ₹317 Cr, margins expand to 27%
PAT +47.09% YoY · revenue +19.57% · margins expanding · beat vs street
₹1,800.27 Cr
+19.57% YoY
₹316.96 Cr
+47.09% YoY
17.03%
+3.2pp YoY
₹19.23
Gland Pharma's consolidated PAT for Q1 FY27 (quarter ended June 30, 2026) came in at ₹316.96 Cr, up 47.1% YoY from ₹215.48 Cr, on consolidated revenue of ₹1,800.27 Cr, up 19.6% YoY from ₹1,505.62 Cr — both clean of one-off items in either period. Sequentially, revenue grew a modest 3.3% QoQ while PAT fell 13.6% QoQ from ₹366.68 Cr; that dip is fully explained by other income dropping to ₹61.2 Cr from ₹111.5 Cr in the seasonally front-loaded Q4, not by core operating weakness.
Q1 FY-2027 vs prior quarters
Margins expanded across the board: EBITDA margin rose to 27% from 24% a year ago (Adj. EBITDA margin 28% vs 25%), and PAT margin widened roughly 330bps to ~17.6% from ~14.3% on a revenue-from-operations basis, per the company's own reconciliation. The expansion was broad-based — CDMO (50% of revenue) grew 20% YoY to ₹891.5 Cr and B2B (50%) grew 19% YoY to ₹908.8 Cr, so neither engine is carrying the other. The US led geographically with 32% YoY growth to ₹981 Cr, aided by four new US molecule launches this quarter (including Multi-Vitamin and Leucovorin calcium) and 3 ANDA filings/7 approvals, taking the cumulative US ANDA count to 389 (342 approved). Standalone PAT of ₹364.39 Cr running ahead of the ₹316.96 Cr consolidated figure reflects continued drag from the European Cenexi subsidiary, which management still targets toward mid-teen EBITDA margins.
The stock went into the print at ₹2,667.3, up 7.6% over the past month of trading.
For context: this is the second-highest quarterly PAT of the last 6 quarters; revenue is at a 6-quarter high.
Management guides for 12-13% constant currency consolidated revenue growth in FY'27, with a long-term CAGR target of 15%, driven by new product launches and strong CDMO traction. This guidance explicitly excludes any potential upside from the GLP-1 business. Consolidated EBITDA margins are expected to remain strong at
— This quarter: beat
Our pre-result preview flagged Street consensus tracking a conservative 9% FY27 revenue growth target, 14 analysts (10 buy) with average price targets of ₹2,189-2,286 pricing the stock for 'on-plan' delivery, and an EBITDA margin heartbeat of 17-19% to watch — this quarter's 20% reported YoY growth and 27% EBITDA margin both clear that bar (the preview's separately-flagged ₹350-380 Cr 'on-plan Q1 revenue' figure looks mismatched against the ₹1,800 Cr actual scale and is disregarded here as unreliable). Against management's own FY27 guidance from the Q4 concall — 12-13% constant-currency revenue growth and 25-26% EBITDA margins — the quarter beats on both revenue pace and margin. Management's press-release framing, crediting 'successful execution of our CDMO strategy and the resilience of our B2B business model' driven by 'recent product launches from CDMO portfolio and strong customer demand,' is borne out by the numbers, with both CDMO and B2B growing in the high-teens/20% range. The quarter also coincided with a new CDMO deal with an unnamed global pharma major (~USD 90-100 Mn annualized revenue potential from CY29) and a sterile-API manufacturing tie-up with Neuland Laboratories, plus the August 25 AGM notice proposing a ₹20/share dividend.
W1
Sugammadex USFDA approval (Jul 29, $1.6 Bn US opportunity) landed after quarter-end — watch Q2 for initial revenue contribution
W2
FY27 guidance of 12-13% constant-currency revenue growth vs Q1's 20% reported growth — track whether pace holds or normalizes toward guided range
W3
Cenexi European turnaround targeting mid-teen EBITDA margins — track quarterly group EBITDA margin trajectory (27% this quarter) for signs of Cenexi contribution
Figures in source were ₹ Million, converted ÷10 to ₹ Cr; both statement checks (total income = revenue+other income; PBT-tax=PAT) matched exactly. No exceptional item in either current or year-ago quarter (the ₹24.35 Cr labour-code provision fell in Q3 FY26/full-year FY26 only). Standalone PAT (₹364.4 Cr) exceeds consolidated (₹317.0 Cr) due to European Cenexi subsidiary drag; no minority interest (100% owned subsidiaries).
Beat FY27 guidance, large CDMO deal; capacity constraints cap near-term
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Buy
confidence 8/10
Grade A
Delivered FY27 revenue at 19.6% YoY, exceeding prior 12-13% guidance. EBITDA margins 28%, on track to 30% target. Clear track record of hitting near-term numbers.
Optimistic
next 1–2 quarters
Very Optimistic
multi-year
Q1 beat prior FY27 guidance (15% cc growth vs prior 12-13%) with 47% PAT growth and 28% EBITDA margins. USD 90-100M CDMO contract signed (revenue CY2029) plus new GLP-1 and liposomal deals provide multi-year 20% CAGR visibility. Key risk: capacity constraints on bag line and ophthalmic (FDA approval timing uncertain) and GLP-1 contributes only tech-transfer fees until FY30-31.
₹1800.3 Cr
Revenue · +19.6% YoY₹317 Cr
Reported PAT · +47.1% YoYExpanding
Margins · vs guidance: CorroboratedDid the claims hold up?
20% YoY revenue growth with healthy profitability
METRevenue ₹1800.3 Cr (+19.6% YoY), PAT ₹317 Cr (+47.1% YoY), NPM 17%
EBITDA margin expansion to 28% adjusted
METAdjusted EBITDA ₹510.2 Cr on ₹1800.3 Cr = 28.3% margin, up from 25% YoY
CDMO contributing 50% of revenue with 20% YoY growth
METCDMO ₹891.5 Cr revenue, 50% mix, 20% YoY growth confirmed on call
U.S. market revenue ₹981 Cr with 32% YoY growth
METStated ₹9,810 million (₹981 Cr) with 32% YoY growth, corroborated
FY27 guidance 15% constant currency is achievable
METConstant currency growth stated as 15% vs reported 20%, difference due to ~5% forex tailwind
Capacity tight on bag line and ophthalmic, FDA approval Q3 could unlock upside
METManagement hedged growth at 15%, upside only if approvals happen by Aug-Sep
Earnings quality
What changed since the last call
FY27 revenue growth guidance raised
UpgradePrior 12-13% constant currency, now 15% (achievable, upside if FDA approvals Q3). Delivered 19.6% YoY, 15% cc. Supports higher end.
EBITDA margin guidance upgraded
UpgradePrior 25-26%, achieved 28% Q1. Now targeting 30% near-term and 35% long-term. Margin expansion outpacing expectations.
4-year CAGR target raised
UpgradePrior 15% CAGR for next 4-5 years. With USD 90-100M deal now signed, targeting ~20% CAGR for next 4 years (equivalent to ~12% of current revenue from new deal alone).
Cenexi margin target softened
DowngradeSubtle: prior messaging suggested mid-teen EBITDA targets for Cenexi. Now targeting double-digit by FY27 year-end. EUR 48M revenue at 4% EBITDA shows turnaround slower than implied.
GLP-1 near-term guidance conservative
NeutralPreviously may have implied upside from GLP-1. Now explicitly stating very limited contribution until FY30-31, only tech-transfer fees. Realistic hedging.
The Q&A
Analysts pressed on constant currency calculation, Cenexi sustainability, and pipeline opportunity size. Management largely held ground—Ravi clarified shipment-date FX basis, Srinivas defended Cenexi turnaround trajectory, deferred on pipeline market sizing (likely IP constraints). Light pushback overall; management credible but some analyst skepticism on guidance math.
Strategic CDMO contract — Saion Mukherjee, Nomura
AnsweredSpecialty pharma mix (30-40% specialty), all Indian sites, 60% US, 30-35% EU, 15-20% ROW. Tech transfer 24 months, products filed quarterly, ramp-up 2029-2030 completion.
More CDMO contracts expected — Saion Mukherjee, Nomura
AnsweredStrategy to offer end-to-end solutions consolidating 80-100 sites. Currently expensive EU manufacturing, we offer cost advantage. Actively pitching to other big pharma.
Capex revised estimate — Saion Mukherjee, Nomura
AnsweredINR 550 Cr this year, will scale up. CDMO-related capex INR 165 Cr (isolator line), Neuland building new block. Original INR 2000 Cr program on track.
Cenexi sustainability — Vivek Gautam, GS Investments
PartialRe-evaluating CAGR, likely 20% next 4 years with new contract. Clarity next quarter. Cenexi profitability improving, target double-digit EBITDA by year-end.
CDMO mix and margin trajectory — Neha M., Bank of America
AnsweredTarget 30% consolidated CDMO near-term, 50-50 for next 2 years, then CDMO may exceed B2B. Current 28% EBITDA, targeting 30%, then 35% long-term with CDMO mix improving.
Cenexi Q2 seasonality — Neha M., Bank of America
AnsweredSome shipments delayed in Q1 due to heat wave. Q2 should benefit, will be better than prior year. Still expect seasonal decline but less sharp.
Cenexi FY27 guidance — Neha M., Bank of America
AnsweredThat's correct. Yes.
GLP-1 scale-up status — Ashish, Leo Capital
AnsweredNew line on track, taking exhibit batches from customers signed last quarters. Signed new sema/tirzepatide contracts for U.S./EU. Transfer next quarter or two. Maintaining 15% growth, possible upside if Canada launch happens.
GLP-1 revenue potential — Ashish, Leo Capital
AnsweredVery limited. Major volume will come U.S. when goes live FY30-31. Not assumed much in next few years except tech-transfer fees. Very difficult to assume numbers, keeping close to chest.
Cenexi revenue/EBITDA correction — Chintan Sheth, Girik Capital
AnsweredEUR 48M revenue and EUR 2M EBITDA. Correction: 48, not 68.
Pipeline product opportunity size — Chintan Sheth, Girik Capital
DodgedCan we come back to exactly how much is the market. [Deferred]
Launch pipeline for FY27 — Chintan Sheth, Girik Capital
PartialLaunched MVI (multivitamin, CGT exclusivity), Dalbavancin (some competition but long-term contracts), Sugammadex. Future launches: we can come back to you later.
Patent-protected CDMO products — Karan Vora, Goldman Sachs
AnsweredCannot reveal customer numbers due to confidentiality. Some 505b2 with patents. No innovative (first-to-market) products currently. Under discussion for future.
Base business growth ex-Cenexi — Karan Vora, Goldman Sachs
AnsweredBase business 24% growth. U.S. 32% growth. Constant currency ~19-20% (removing ~5% forex gain).
Neuland and liposomal contracts — Saion Mukherjee, Nomura
PartialNeuland: strategic collaboration, revenue not disclosed, building new block, eases capacity constraint. Liposomal: USD 3B market (USD 1.6B current, USD 600-700M US), in-licensing for U.S./EU, tech transfer, revenue FY30, patent-protected.
Complex ANDA pipeline — Saion Mukherjee, Nomura
AnsweredYes, most of the big products are post-FY29. Different stages, some clinical, some exhibit. Big microsphere products specifically post-FY29.
Old product strategy (Para 1-3) — Saion Mukherjee, Nomura
AnsweredSome products developed 15 years ago when ANDA was cheaper. Companies are exiting, but as injectable player we capture value. Several 'old' products now doing well. Portfolio diversification necessary.
Constant currency growth — Rahul Jeewani, IIFL
AnsweredUse shipment-date FX rates, not uniform across every transaction. For guidance, we assume constant currency, FX is unpredictable. All forward projections based on constant currency.
Tech transfer CDMO margins — Rahul Jeewani, IIFL
AnsweredIP-owned shares profit with front-end partner. CDMO has 2 types: B2B tech transfer (smaller), commercialized products from expensive U.S./EU sites (larger, better leverage). New deal is mix, has better margin profile than IP-owned.
CDMO growth drivers — Alankar Garude, KIE
AnsweredPortfolio running out of large products (driver 1). Big pharma with expensive manufacturing base in EU seeking India alternative (driver 2). We offer end-to-end solution consolidating 60-70 sites (driver 3). Operational leverage on manufacturing advantage.
Profit share — Alankar Garude, KIE
AnsweredAbout 9%.
NDDS project timeline — Alankar Garude, KIE
AnsweredNDDS project FY28 commercialize FY29, USD 25-30M potential revenue.
Guidance
FY27 15% constant currency growth
HighRaised from prior 12-13%. FDA approvals (Q3) could push above 15%. Current run rate supports this.
Next 4 years ~20% CAGR
MediumDependent on USD 90-100M CDMO ramp from CY2029, other contract discussions still ongoing. Management to clarify next quarter.
30% EBITDA margin near-term
HighCurrently at 28%, incremental 200 bps achievable with CDMO mix and operating leverage. Cenexi turnaround supporting.
35% EBITDA margin long-term
MediumDepends on CDMO becoming 50%+ of business and reaching mid-20s margins. Timeline unclear (3-4 years mentioned).
₹550 Cr capex in FY27
HighINR 2,000 Cr total program, ₹1,132 Cr in Q1, scale-up in brownfield/greenfield expansion.
Risks the call surfaced
Capacity constraints
HighBag line and ophthalmic lines at tight capacity. FDA approval expected Q3 but no guarantee. If approval delayed to Q4, FY27 revenue growth will miss 15% guidance.
Cenexi turnaround sustainability
MediumCenexi EBITDA only 4% on EUR 48M revenue (EUR 2M EBITDA). Prior messaging suggested mid-teen EBITDA targets. Now targeting just double-digit by FY27 year-end. If European demand weakens further, targets at risk.
Currency headwinds reversal
MediumQ1 revenue reported at 20% but constant currency only 15%, implying 5% forex tailwind from USD/INR depreciation. If INR strengthens in coming quarters, reported growth will decelerate to 10-12% even if operational growth stays at 15%.
GLP-1 market timing and competition
MediumGLP-1 revenue only from FY30-31. Market already crowded by then; multiple CDMO players and in-house manufacturing ramps by competitors. Management currently taking only tech-transfer fees until FY30, very conservative outlook.
Large CDMO deal execution risk
HighUSD 90-100M CDMO contract requires flawless 24-month tech transfer (Sep 2026 start), product filings from CY2027, and commercialization from CY2029. Any delay in tech transfer or FDA/EMA approvals will push revenue forward, impacting 2029-2030 forecast.
Management
Score 8/10. Transparent and detailed. Corrected Cenexi revenue mid-call (EUR 48M vs EUR 68M). Explained constant currency vs reported growth with FX basis clarification. Hedged appropriately on GLP-1 (no over-promising) and pipeline launches (deferred specifics likely due to IP constraints). Strong track record this quarter (hit 19.6% revenue growth vs prior 12-13% guidance, 47% PAT growth, 28% EBITDA margin vs prior 25-26%). U.S. business growing 32%, CDMO on plan, new products launching. Cenexi turnaround evident but slower than prior messaging suggested (4% vs mid-teen target implies prior guidance was overstated).
1 · Q3 FY27 (Oct-Dec)
FDA approval of bag line and ophthalmic line unlocks capacity
2 · Sep 2026
Tech transfer for USD 90-100M CDMO deal commences
3 · CY 2029
USD 90-100M CDMO contract revenues commence, ramp through CY30
Key risk: capacity constraints on bag line and ophthalmic (FDA approval timing uncertain) and GLP-1 contributes only tech-transfer fees until FY30-31.
The Reported Beat Masks Steady Execution—and a Capacity Gate
Q1 reported 47% profit growth on a 5% forex tailwind. The operational story is steadier: constant currency growth matched raised guidance, not exceeded it. Upside depends on FDA-timed capacity expansion and a USD 100M CDMO deal revenue starting 2029.
+19.6%
YoY, ₹1800.3 Cr
+15%
Operational baseline; matches raised guidance
~4.6%
INR depreciation (USD/INR moved ~5%)
₹317 Cr
+47.1% YoY
-13.6%
QoQ from ₹367 Cr; ₹36 Cr forex loss vs Q4's ₹508 Cr gain
On the surface, the quarter looks exceptional: 20% revenue growth, 47% profit growth, margins expanding. But unpack it, and the narrative shifts. Of the 19.6% reported revenue growth, approximately 4.6% came from INR depreciation—a currency tailwind, not operational strength. Constant currency growth is 15%, which is exactly where management raised guidance to (from 12–13% prior). The operational beat exists, but it is measured and constrained, not explosive. And therein lies the story.
Where the reported growth came from
The sequential profit picture is more telling. PAT of ₹317 Cr is up 47% YoY but down 13.6% quarter-on-quarter from ₹367 Cr in Q4 FY26. The difference: Q1 had a ₹36 Cr forex loss, while Q4 benefited from a ₹508 Cr forex gain. Strip out the forex swing, and the quarter's organic momentum looks more modest. This matters because INR strength—a plausible scenario if global risk appetite shifts—would reverse the forex tailwind and reduce reported growth to 10–12% even if constant currency stays at 15%.
Claims vs. reality: what holds up
CDMO is the growth engine, contributing 50% of revenue at 20% YoY growth
U.S. market remains the strongest region, growing 32% YoY
EBITDA margin expanded to 28%, on track to 30% by year-end
Constant currency growth of 15% is sustainable and guided for FY27
Cenexi reached profitability milestone (mid-teen EBITDA margins by now)
Capacity constraints on bag line and ophthalmic are the main growth gate
The Cenexi claim is the outlier. Prior messaging suggested mid-teen EBITDA margins as a medium-term target. Q1 delivered: EUR 48M revenue, EUR 2M EBITDA, a 4.2% margin. Management's revised target is now "double-digit by FY27 year-end." This is a quiet walk-down. If European demand softens further, even double-digit margins are at risk.
What changed on this call
Management raised guidance across three dimensions. FY27 revenue growth: raised to 15% constant currency (from prior 12–13%), matching Q1's delivery. EBITDA margins: raised to 30% near-term (from 25–26%), with a long-term target of 35%. Q1 already achieved 28%, putting the company on track. 4-year CAGR: raised to approximately 20% (from prior 15%), contingent on the large CDMO deal signed this quarter. The deal is material: USD 90–100M peak revenue from a specialty pharma client, 55 SKUs across oncology and non-oncology, tech transfer beginning September 2026 over 24 months. Revenue generation starts in calendar 2029 and ramps through 2030. This single contract could add ~12% to current revenue at peak. Management also signed new GLP-1 contracts (semaglutide and tirzepatide) for U.S. and EU markets, and in-licensed a liposomal platform from China (USD 3B market potential, revenue FY30 onwards). These are optionality, not near-term drivers.
The debate
The bull-bear ledger
Q1 delivered 15% cc growth, matching (not exceeding) raised FY27 guidance
EBITDA margin 28% achieved, on track to 30% near-term; 3 pts YoY expansion
USD 90–100M CDMO deal with 55 SKUs and clear tech-transfer timeline (Sep 2026 start)
CDMO now 50% of revenue, growing 20% YoY; highest-growth segment
U.S. market strength: ₹981 Cr revenue, +32% YoY, 54% of total
Reported revenue growth inflated by ~5% forex tailwind; operational growth is steady, not exceptional
Sequential PAT down 13.6% QoQ; earnings volatility from forex swings
Capacity constraints on bag line and ophthalmic are gating growth; FDA approval timing uncertain (expected Q3)
Cenexi turnaround slower than prior messaging (4% EBITDA now, was mid-teen implied)
USD 90–100M CDMO deal revenue only from CY2029; near-term growth still capacity-constrained
GLP-1 major volume only from FY30–31; near-term contribution limited to tech-transfer fees
Risks, ranked by how much they should concern a holder
Capacity constraints delay FDA approval (bag line, ophthalmic)
HighExpected approval is Q3 FY27. If delayed to Q4, FY27 revenue growth will decelerate below 15% guidance. A 6-month delay pushes 12–15% of potential growth into FY28.
USD 90–100M CDMO deal execution slips
HighTech transfer begins Sep 2026 over 24 months. Any delay in customer approval or manufacturing ramp pushes revenue beyond 2029, deferring the 20% CAGR narrative.
Cenexi turnaround stalls
MediumCurrently 4% EBITDA on EUR 48M revenue. If European demand softens or restructuring costs persist, even 'double-digit by year-end' is at risk, weighing on consolidated margins.
INR strength reverses forex tailwind
MediumQ1 benefited from ~5% forex tailwind. If INR strengthens, reported growth decelerates to 10–12% even if constant currency stays at 15%. Street typically focuses on reported numbers.
GLP-1 market saturation by FY30
MediumMajor GLP-1 revenue only from FY30–31. By then, competition will be mature. Management is appropriately conservative, but upside optionality may be overstated.
How the street is positioned
The market rewarded the reported beat. The stock rallied 9.64% on day-1 (announcement), added 11.26% by day-3, and held 9.11% gains by day-5. Momentum has sustained. Current price action: ₹2858.6 as of August 18. The stock is 5.96% below its all-time high but still +81.66% off its 52-week low. RSI is 70.3, signaling overbought conditions—room for consolidation or profit-taking if near-term catalysts (FDA approval) stall. Ownership flows are mixed. FII increased holdings by 1.44 percentage points to 8.74% (positive signal for institutional conviction). Domestic investors (DII) trimmed by 2.91 percentage points to 30.44%, consistent with profit-taking near all-time high. Promoter holding steady at 51.77%. The stock's high price and overbought RSI leave limited upside room without further operational acceleration. Any near-term disappointment (delayed FDA approval, softer Cenexi recovery, INR strength) will be punished in this setup.
What to watch next
1 · Q3 FY27 (Oct–Dec): FDA approvals unlock capacity
Bag line and ophthalmic line approvals are expected Q3. If approved on schedule, capacity expands and FY27 growth accelerates above 15%. Delay to Q4 is a red flag for execution risk.
2 · Sep 2026: USD 90–100M CDMO tech transfer begins
Quarterly updates should track progress through October call. Look for product transfer pace, customer approval timelines, and any delays. Early momentum validates the 2029 revenue ramp assumption.
3 · Cenexi profitability trajectory
Q1 delivered 4% EBITDA (EUR 2M on EUR 48M revenue). Target is 'double-digit by FY27 year-end' (9–10% or more). Q2 and Q3 results will show if the turnaround is real or just cost-cutting.
4 · Currency headwinds: INR strength reversal
If USD/INR depreciates (INR strengthens), the 5% forex tailwind reverses. A 3–5% forex headwind would push reported growth to 10–12% even if operations stay at 15%.
Gland delivered a sound quarter. The operational story is steady: constant currency growth matched guidance (not exceeded it), margins expanded as promised, and a material CDMO deal arrived. But the reported beat is overstated by forex, and near-term growth is gated by FDA-timed capacity. This is a mid-cycle stock in a high-quality franchise, not a step-change inflection. Management is credible (A-grade track record), but Cenexi's slower turnaround and capacity constraints weigh on conviction. The USD 90–100M deal and 20% CAGR target are compelling, but revenue only starts in 2029. For holders, the stock's overbought RSI (70.3) and proximity to all-time high leave limited upside room. For new entrants, a consolidation or pullback on near-term disappointment (delayed FDA, softer Cenexi, INR strength) would be a healthier entry. The number to track from here: constant currency revenue growth vs. 15% FY27 guidance. It is the operational north star. Reported growth is forex-dependent and volatile.
Post-Q4 euphoria: Can Gland sustain momentum with Sugammadex on the board?
After a 97% PAT blowout in Q4 FY26, Gland enters Q1 tracked by the Street to deliver double-digit growth and margin stability. The USFDA approval for Sugammadex—a $1.6 billion US market—lands this quarter; Street consensus says buy, but price targets suggest modest downside from ₹2,579 levels. Watch for Sugammadex traction and whether FY2027 guidance can hit the consensus 9% revenue target.
The setup: Q4 was a breakout—now the market wants proof of sustainable run-rate
Gland Pharma's Q4 FY26 delivered 22% revenue growth and a stunning 97% PAT surge—the kind of beat that invites scrutiny: was it organic, or driven by one-off tail-winds? Heading into Q1 FY27 (results Aug 10), the equity is already near all-time high at ₹2,579.2, pricing in that momentum. The Street's task: determine if the company is tracking the full-year consensus of ~₹73.6b revenue (9% YoY growth) and 22% EPS growth. The real test won't be the number—it'll be the margin profile and early traction from Sugammadex's USFDA-approved launch (just approved Jul 29, with $1.6 billion addressable market in the US). Any guidance tweak on FY27 targets will move the stock more than the quarter itself.
~₹350–380 Cr
Implies 15–20% YoY growth, sustaining Q4's pace; a reset below ~₹340 Cr would flag demand softness
EBITDA margin: monitor for 17–19% range
Q4's PAT margin benefited from operating leverage; Street watches if Q1 can hold without a step-down
Early uptake signals
Too early for material Q1 revenue, but mgmt. commentary on launch readiness + US GP competitive stance will set medium-term story
Track full-year implies
Street expects ~₹73.6b revenue (9% growth) & 22% EPS CAGR; Q1 print + CFO guide will validate or force reset
What a strong Q1 vs. a weak Q1 looks like
Strong quarter: Revenue ≥₹370 Cr (18%+ YoY), EBITDA margin 18–19%, PAT touches ₹85–90 Cr. Management flags Sugammadex hitting distribution ahead of expectations, no guidance downgrade on FY27, and a clear path to the consensus ₹73.6b full-year run-rate. This sets up a re-rating higher toward Street targets. Weak quarter: Revenue slips to ₹330–345 Cr (single-digit to low-teen growth), margins compress below 17% EBITDA, PAT underwhelms. On the call, no color on Sugammadex traction, and/or FY27 full-year guidance is cut. The stock would face selling, especially given current valuation near ATH and the pending ₹20 dividend (record date Aug 11) already baked into the equity.
On track to FY2027 full-year?
Yes, tentatively. Q4 FY26 revenue of ₹17,428 Cr (22% YoY growth) and consolidated PAT of ₹366.68 Cr (97% YoY growth) set a strong base for the full year. Street consensus of ₹73.6b revenue (9% YoY) and 22% EPS growth imply a normalized, mid-teen growth trajectory post-Q4's outperformance. Q1 needs to land in the high-teens growth zone (₹15–19% YoY) to stay on pace; anything materially below that flags pressure on summer monsoon demand (often soft for generics) or competitive pricing headwinds. The USFDA approval for Sugammadex is a positive inflection, but it won't move the needle significantly in Q1—upside from that comes in Q2–Q3 as the US ramp accelerates. For now, the Street views the company as tracking, not accelerating. No major guidance tweaks expected unless margin assumptions shift.
Since last quarter: filings scan
1 · USFDA approval for Sugammadex Injection (Jul 29)
Final nod for 200 mg/2 mL and 500 mg/5 mL; $1.6 billion US market for reversal of neuromuscular blockade. Gland launched Day 1 via marketing partner. Competitive window open until other generics win final approval—no timeline on that yet. Upside driver for FY27–FY28, but margin erosion risk if the category becomes crowded. Positive, but tempered by price-erosion playbook in US generics.
2 · IGST demand + penalty (Jul 16): ₹7.05 Cr flagged
Order from Principal Commissioner of Customs, Hyderabad: ₹3.53 Cr IGST demand + ₹3.53 Cr penalty (total ₹7.05 Cr) related to past import/export compliance. Company's appeals path not detailed in the notice yet. If upheld, it's a one-time charge (manageable at ~2% of quarterly PAT), but adds to FY27 headwinds if multiple challenges are pending. Negative, but low materiality; watch for disclosure on appeals in the Aug 10 call.
3 · 48th AGM on Aug 25, ₹20 dividend proposed (Jul 31)
Board approved final dividend of ₹20 per share (2000% on ₹1 FV) for FY26, record date Aug 11, 2026. High payout ratio signals confidence in cash generation, also aligns with Board's confidence on FY27 run-rate. Cash outflow manageable; EPS accretion story intact. Positive for sentiment; no surprise on the quantum given full-year FY26 performance.
4 · Board changes: two new independent directors (Jun 15, Jul 20–30)
Mr. Udo Jahannes Vetter re-appointed for second term; Mr. William Robert Keller newly appointed; Mr. C.S.N. Murthy stepped down (conflict of interest). Mr. Satyanarayana Murthy Chavali also resigned (Jun 16). Governance housekeeping, no operational impact flagged. Routine.
5 · ESOP grants: 690,019 options to 124 employees (May 15) + 16,790 to 3 employees (Jul 30)
Steady talent retention via stock options under ESOP 2025. Normal course; dilution manageable. Routine.
6 · BRSR submission (Jul 31)
Business Responsibility and Sustainability Report filed for FY26. Compliance item; no new disclosures on material ESG risks detected. Routine.
The headline since Q4: Sugammadex approval is the headline, IGST demand the footnote. The approval opens a new $1.6b addressable market in the US and signals Gland's expansion into higher-margin specialty generics. The IGST matter is a low-materiality tax compliance item; even if fully upheld, it's a single-quarter charge. Ownership remains stable (FII 7.30%, DII 33.35%, promoter 51.83% as of Q4 FY26); no signs of insider selling or promoter pledges. The Aug 25 AGM and ₹20 dividend provide a positive catalyst post-results, anchoring retail sentiment.
Three things to watch on Aug 10
1. Q1 revenue & margin bridge: Is Gland delivering 15–20% YoY revenue growth with stable (≥17%) EBITDA margin? Any sequential margin slip would signal competitive pressure or mix headwind—the Street is price-sensitive to that. 2. Sugammadex launch readiness & US GP outlook: How much early uptake has Gland seen post-Jul 29 approval? Is management confident in capturing 10–15% of the $1.6b addressable market in Y1, or more conservative? Any color on competitive timelines (other generics approval window) matters for FY27–FY28 upside. 3. FY27 full-year guidance confirmation: Street expects ~₹73.6b revenue (9% YoY) and 22% EPS growth. Mgmt. will either reaffirm, raise, or quietly cut guidance on the Aug 10 call. A cut, even modest, would trigger re-rating below current price targets. Raises are unlikely; confirmation + Sugammadex color could hold the stock near ATH.
Gland Pharma enters Q1 FY27 results as a momentum play on the back of Q4's 97% PAT beat—but the Street is asking the maturity question: can the company deliver normalized double-digit growth and stable margins while launching Sugammadex into a $1.6 billion US market? The USFDA approval is a strategic win, but it won't offset a soft quarter if domestic demand falters or FY27 guidance wobbles. Stock is trading near all-time high and price targets suggest modest downside; the results must reaffirm the Street's 9% FY27 revenue growth and 22% EPS thesis to hold current levels. Watch revenue momentum, margin stability, Sugammadex early traction, and any tweak to full-year guidance—that's the trifecta that will determine whether Gland sustains the rally post-Aug 10.